Compare ResMed Inc. (RMD) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs J M Smucker Co — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while J M Smucker Co trades at $123.61 (market cap $13.32B). The key difference: ResMed Inc. is far larger — about 2.4× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.59%). Which is the better fit depends on your goals.
| RMD | SJM | |
|---|---|---|
Market Cap | $31.89B | $13.32B |
Sector | Health | Consumer Staples |
52-Week High | $283.28 | $132.34 |
52-Week Low | $182.82 | $89.53 |
Enterprise Value | $31.24B | $20.17B |
Dividend Yield | 1.19% | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal from moving averages but bearish oscillators. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.24 surpassing the $2.22 estimate. The company reported a net loss of $1.23 billion for 2025, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $144.78 price target, indicating potential upside. A dividend of $1.12 per share is scheduled for payment on September 1, 2026.
The outlook is cautiously optimistic, driven by strong earnings performance and raised guidance, but high valuation ratios and recent insider sales pose risks. Debt levels remain elevated with a debt-to-asset ratio of 43.71% in 2025. Investors should weigh robust operational cash flow against margin pressures and competitive challenges in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
